| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 09/08/2006 | WO2006092515A1 Transgenic mice and use thereof as an experimental model |
| 09/08/2006 | WO2006036777A3 Diagnosis of diseases associated with cox-2 expression |
| 09/08/2006 | WO2004075724A3 Serotonin and catecholamine system segment optimization technology |
| 09/08/2006 | WO2004053106A3 Profiled regulatory sites useful for gene control |
| 09/08/2006 | CA2600912A1 Transgenic mice and use thereof as an experimental model |
| 09/08/2006 | CA2599520A1 Radioisotope labelled biological compositions, and their use in accelerator mass spectrometry |
| 09/08/2006 | CA2575611A1 Covalent tethering of functional groups to proteins and substrates therefor |
| 09/07/2006 | US20060199859 Topical medicaments and methods for photodynamic treatment of disease |
| 09/07/2006 | US20060199833 Novel chemiluminescent compounds and their use |
| 09/07/2006 | US20060199787 N-(2-acetamidoethyl)phosphonoformamide; inhibiting effect on zinc-containing proteinases, inhibiting cancer cells |
| 09/07/2006 | US20060198901 Drugs, bio-affecting and body treating compositions |
| 09/07/2006 | US20060198842 treating skeletal muscle atrophy with a corticotropin releasing factor 2 receptor (CRF2R) agonist such as Sauvagine, urocortin II or an antibody |
| 09/07/2006 | US20060198840 increased in vivo half-lives due to the presence of an immunoglobulin G (IgG) constant domain; pharmacokinetics; diagnosis or immunotherapy; antibody conjugates; palivizumab |
| 09/07/2006 | US20060198823 Compositions and methods for treating viral infections |
| 09/07/2006 | US20060198789 Target validation assay |
| 09/07/2006 | US20060198788 Method of evaluating compound efficacious in treating obesity by using slc25a10 |
| 09/07/2006 | US20060198787 Biomarkers for predicting liver fibrosis treatment efficacy |
| 09/07/2006 | DE202006007665U1 Chemically activatable capsule for continuity check and treatment of intestinal tract, comprises interior covering with opposite discharge openings and with a filling from granulates, powder, gel or liquid, and outer covering |
| 09/07/2006 | DE102005008765A1 Kontrastmittel auf der Basis von Bakteriophagen, Verwendung und Verfahren zu deren Herstellung Contrast agents based on bacteriophages, use and process for their preparation |
| 09/06/2006 | EP1698350A1 Porphyrin-based compounds for tumor imaging and photodynamic therapy |
| 09/06/2006 | EP1696965A1 Assembly of gas-filled microvesicle with active component for contrast imaging |
| 09/06/2006 | EP1696957A2 Radiation therapy and medical imaging using uv emitting nanoparticles |
| 09/06/2006 | EP1696784A2 Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof |
| 09/06/2006 | EP1490032B1 Processes for manufacturing polymeric microspheres |
| 09/06/2006 | CN1829735A Imaging agents |
| 09/06/2006 | CN1829536A Improved intra-dermal delivery of biologically active agents |
| 09/06/2006 | CN1273197C Construction method for mouse skin allergy animal model |
| 09/05/2006 | US7101864 N-(2-acetamidoethyl)phosphonoformamide; inhibiting effect on zinc-containing proteinases, inhibiting cancer cells |
| 09/05/2006 | US7101532 Liposome containing hydrophobic iodine compound |
| 09/05/2006 | CA2143642C Immunoreactive peptides from epstein-barr virus |
| 08/31/2006 | WO2006091861A2 Compositions and methods relating to cns lymphoma |
| 08/31/2006 | WO2006090706A1 Contrast agent-removal system and method of activating the contrast agent-removal system |
| 08/31/2006 | WO2006090259A2 A method for screening photosensitive compound |
| 08/31/2006 | WO2006065146A3 Fluorescent contrast agents |
| 08/31/2006 | US20060194316 Stromal differentiated neuron-like cells for use in treatment of neurodegenerative, ischemic, spinal cord and ataxic disorders; tissue engineering; regenerative medicine |
| 08/31/2006 | US20060194030 Methods for identification and verification |
| 08/31/2006 | US20060193871 transmission and, or amplification of signal; oral or enteric administering, dissolving, absorption; peptide yy; obesity therapy |
| 08/31/2006 | US20060193782 Abuse-proofed dosage form |
| 08/31/2006 | US20060193781 Magnetic resonance imaging of metal concentrations |
| 08/31/2006 | US20060193780 cyanine dyes and/or with lipophilic side chains; to detect stained cells both in vivo and in vitro; increased signal to noise ratio for rapidly labeling; improved solubility |
| 08/31/2006 | US20060193779 Configured for placement onto a person's tooth, anti-stokes up converter to be combined with polymerizable resin; can be formulated to blend with a person's tooth, and also be capable of changing color to be distinguishable from the tooth when to long wavelength light; sealants, varnishes, restoratives |
| 08/31/2006 | US20060193778 Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| 08/31/2006 | US20060193777 Method of screening compounds for potential efficacy for the treatment of signs of aging |
| 08/31/2006 | US20060193776 Screening methods employing zebrafish and the blood brain barrier |
| 08/30/2006 | EP1696030A1 TIE ligand homologues |
| 08/30/2006 | EP1696029A1 TIE ligand homologues |
| 08/30/2006 | EP1695960A1 Near-infrared fluorescent contrast medium |
| 08/30/2006 | EP1695702A2 Treatment of metastatic disease |
| 08/30/2006 | EP1695696A1 Liposome |
| 08/30/2006 | EP1694367A1 Mri contrast medium composition for oral administration |
| 08/30/2006 | EP1694366A2 Tungsten particles as x-ray contrast agents |
| 08/30/2006 | EP1694365A1 Optical imaging contrast agents |
| 08/30/2006 | EP1583563B1 Method for the production of hyperpolarized 129xe |
| 08/30/2006 | EP1283729B1 Tc and re carbonyl complexes prepared from pertechnetates and perrhenates |
| 08/30/2006 | EP1171604B1 Dna sequence and recombinant production of a graminae allergen |
| 08/30/2006 | EP0755270B1 Microcapsules, method of making and their use |
| 08/30/2006 | CN1824332A Method for determining suitability of various contrast agents for the imaging examination of the patient and uses of the ligand contained in a selected contrast agent |
| 08/30/2006 | CN1824331A Liver specificity ultra micro paramagnetism MRI centrast medium and its preparation method |
| 08/30/2006 | CN1824330A Preparation method of visible rhinopharyngocele cancer blood vessel shaping model |
| 08/30/2006 | CN1824329A Preparation method of visible rhinopharyngocele cancer model |
| 08/30/2006 | CN1824311A Preparation for the prophylaxis of restenosis |
| 08/30/2006 | CN1824083A Health care function of mosailais wine and its component analysis |
| 08/29/2006 | US7098187 for inhibiting endothelial cell proliferation or endothelial tube formation in in vitro or in vivo bioassay |
| 08/29/2006 | US7097826 Conjugates of ditetratriethylamine pentacarboxylic acid (DTPA) and bisaminoethanethiol (N2S2); for magnetic resonance (MR) imaging; for tumor visualization and necrosis |
| 08/29/2006 | US7097825 Methods and reagents to acquire MRI signals and images |
| 08/29/2006 | CA2373410C A2a receptor agonists |
| 08/24/2006 | WO2006089113A2 Biomarkers for predicting liver fibrosis treatment efficacy |
| 08/24/2006 | WO2006088476A2 Carboranylporphyrins and uses thereof |
| 08/24/2006 | WO2006087145A1 Device and method for identifying mycotoxins |
| 08/24/2006 | WO2006087144A2 Contrast agents for nuclear spin tomography carried out by means of overhauser effect |
| 08/24/2006 | WO2006086870A1 Aprotinin polypeptides for transporting a compound across the blood-brain barrier |
| 08/24/2006 | WO2006050058A3 Methods of detection and therapy of inflamed tissues using immune modulation |
| 08/24/2006 | WO2006039678A3 Establishment of highly metastatic cell lines using nog mice |
| 08/24/2006 | US20060188447 Process for the production of an abuse-proofed dosage form |
| 08/24/2006 | US20060188445 Assay for compounds that protect against sensory hair cell death and compounds identified by same |
| 08/24/2006 | US20060188444 Method for monitoring patient or subject compliance with medical prescriptions, and formulation for use in the method |
| 08/24/2006 | US20060188443 Diagnostic composition for diabetes type-2 and impaired glucose tolerance, and methods of use |
| 08/24/2006 | US20060188437 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 08/24/2006 | DE102005007223A1 Kontrastmittel für die Kernspintomographie unter Nutzung des Overhauser-Effekts Contrast agents for magnetic resonance imaging using the Overhauser effect |
| 08/24/2006 | DE102004026102B4 Verfahren zur Herstellung von 1-Hydroxymethyl-1,3,5-triazapentan, Trihydrochlorid A process for the preparation of 1-hydroxymethyl-1,3,5-triazapentan, trihydrochloride |
| 08/24/2006 | CA2597958A1 Aprotinin polypeptides for transporting a compound across the blood-brain barrier |
| 08/24/2006 | CA2567468A1 Carboranylporphyrins and uses thereof |
| 08/23/2006 | EP1692936A1 Method for targeted conditional DNA recombination in mice using the cre-ert2 fusion protein |
| 08/23/2006 | EP1692636A2 Methods, program products and systems for single and multi-agent dosing |
| 08/23/2006 | EP1692521A1 Rbp4 in insulin sensitivity/resistance, diabetes, and obesity |
| 08/23/2006 | EP1692507A1 Water-soluble compound |
| 08/23/2006 | EP1691846A1 Peptides whose uptake by cells is controllable |
| 08/23/2006 | EP1691845A1 Compounds containing matrix metalloproteinase substrates and methods of their use |
| 08/23/2006 | EP1691791A2 Capsules of multilayered neutral polymer films associated by hydrogen bonding |
| 08/23/2006 | EP1691664A2 Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
| 08/23/2006 | EP1363920B1 Modified psma ligands and uses related thereto |
| 08/23/2006 | EP1037673B1 Charged lipids and uses for the same |
| 08/23/2006 | CN1270780C 栓塞材料 Embolic material |
| 08/22/2006 | US7094580 Methods for producing pure perlecan and other heparan sulfate proteoglycans |
| 08/22/2006 | US7094566 IL-17 receptor like molecules and uses thereof |
| 08/22/2006 | US7094424 Cationic lipid compositions targeting angiogenic endothelial cells |
| 08/22/2006 | US7094391 oral Lime disease vaccination using pure Outer surface protein A specific serum Immunoglobulin A antibodies; immunotherapy |
| 08/22/2006 | US7094369 Forming beads of a predetermined size from a starting material which is a template polymer or ice; contacting the beads with a structural polymer; crosslinking the structural polymer |
| 08/22/2006 | CA2331812C 13c glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control |
| 08/17/2006 | WO2006086677A2 Endohedral fullerenes as spin labels and mri contrast agents |